ALXOALX Oncology Inc.Finished
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Gastric Adenocarcinoma
14Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due May 2024, none posted yet
Counts until it's fixed
- +3.9
2 insiders sold shares within a month
Since Aug 17, 2026 · was worth 10, fading over time
Worry score14
Score over time
- Stage
- Phase 2/3
- Patients
- 127 (final count)
- Started
- Jan 15, 2022
- Main results expected
- May 24, 2024
- Fully finished
- Jun 30, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 2
Measured over: Last randomized patient on study at least 16 weeks
Phase 3
Measured over: From the date of randomization to the date of death (due to any cause), up to 36 months postdose
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-05-24, no fading
- insider_selling_cluster: base 10, now 3.9, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05002127 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC